Summary
Due to increasing regulatory requirements, the need for quality study and patient safety data is critical as we work together to bring our clients’ novel treatments to patients. PRA Health Sciences is diligently working to meet our clients’ data demands through the substantial growth of our Data Monitoring Committee (DMC) services over recent years. Staffed by a global team of experts, PRA’s dedicated DMC Unit ensures our clients’ projects meet the most stringent regulatory requirements.
Register to download
Data Monitoring Committee Unit
You may also be interested in:
Fact Sheet
Pharmacogenomics in Pain Management
Pharmacogenomics in Pain Management. In the US alone there are an estimated 100 million adults suffering from chronic pain. Pharmacogenomics and…
Poster
Predicting Screen Failure Rates of Human Abuse Potential Studies
Human Abuse Potential (HAP) studies are required for New Drug Approvals of all drugs that have a potential psychoactive effect. The steps of…
Publication
Successful Adaptation to the Evolution of Complex Dose Escalation Within a Large Master Protocol Basket Design Across IO Co-Therapies
A case study describing a Phase I dose escalation and cohort expansion study of an immune checkpoint inhibitor in patients with advanced solid…